Last Updated : September 27, 2023
Details
Generic Name:
rimegepant
Project Status:
Withdrawn
Therapeutic Area:
Migraine, prevention
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Nurtec ODT
Project Line:
Reimbursement Review
Project Number:
SR0797-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of episodic migraine in adults with less than 15 migraine days per month who have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the preventive treatment (prophylaxis) of episodic migraine in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 04-Jul-23 |
|---|---|
| Call for patient/clinician input closed | 25-Aug-23 |
| Submission received | 15-Aug-23 |
| Submission accepted | 29-Aug-23 |
| Review initiated | 30-Aug-23 |
| Clarification: - Submission temporarily suspended -Voluntarily withdrawn by the sponsor on 26 Sep 2023 | |
Last Updated : September 27, 2023